Lineage Cell reports OpRegen Phase 1/2a data: 7.6-letter visual gain in Cohort 4 at 12 months

Lineage Cell Therapeutics, Inc.

24 patients treated; no cases of rejection or intraocular inflammation reported.
Cohort 4 (impaired vision) averaged 7.6-letter gain in study eye at Month 12; 25% gained ≥15 letters.
Five Cohort 4 subjects with OpRegen delivered to most/all GA area had average 12.8-letter gain and outer retinal structure improvement.
Majority of AEs were mild (Cohort 4: 93%); most common ocular AEs related to surgical procedure (conjunctival hemorrhage, epiretinal membrane).
OpRegen developed under worldwide collaboration with Roche and Genentech; larger controlled study needed to confirm findings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.